EUVIMEDEUVIMED entdecken
Open Access

First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center

Avi Shah, Ankit Agarwal, Vishva Rajpuria, Shiv Ghodasara, Jagdish Swami, Vibhav Kanth, Hiren Dangar, Ashish Jakhetiya

Cureus · 24.07.2026

DOI: 10.7759/cureus.113313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 24.07.2026. Verfasst von Avi Shah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Geetanjali Medical College, Udaipur, IND. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

dual immune checkpoint inhibitorsmalignant pleural mesothelioma (mpm)real world datasafety and efficacyunresectable pleural mesothelioma

Autor:innen und Institutionen

  • Medical Oncology, Geetanjali Medical College, Udaipur, IND.
  • General Medicine, Smt. Nathiba Hargovandas Lakhmichand (NHL) Municipal Medical College, Ahmedabad, IND.
  • Surgical Oncology, Geetanjali Medical College, Udaipur, IND.

Zitieren

APA

Shah, A., Agarwal, A., Rajpuria, V., Ghodasara, S., Swami, J., Kanth, V., Dangar, H., & Jakhetiya, A. (2026). First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center. Cureus. https://doi.org/10.7759/cureus.113313

Vancouver

Shah A, Agarwal A, Rajpuria V, Ghodasara S, Swami J, Kanth V, et al. First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center. Cureus. 2026. doi:10.7759/cureus.113313

BibTeX
@article{Shah2026,
  author = {Shah, Avi and Agarwal, Ankit and Rajpuria, Vishva and Ghodasara, Shiv and Swami, Jagdish and Kanth, Vibhav and Dangar, Hiren and Jakhetiya, Ashish},
  title = {First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.113313}
}
Kostenlos starten →